Establishment Labs Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Guidance

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the fourth quarter and full year ended December 31, 2025 and provided 2026 guidance. Fourth Quarter Highlights and Outlook Fourth quarter revenue of $64.6 million, an increase of 45.2% from the year-ago period. 2025 revenue of $211.1 million, an increase of 27.2% over 2024. Motiva U.S. revenue in the fourth quarter of $17.3 million, and full year U.S. revenue of $45.6 million. Fourth quarter net loss from operations of $3.9 million, a 79% reduction compared to a net loss of $18.7 million in the year-ago period. Fourth quarter adjusted EBITDA of positive $5.5 million, an $18.6 million increase compared to a loss of $13.1 million in the year-ago period. Cash balance of $75.6 million as of December 31, 2025, an increase of $4.9 million compared to Q3 2025. 2026 revenue guidance of $264 million to $266 million, an increase of 25.1% to 26.0% over 2025. 2027 revenue growth projected to be at least 25%. “Our growth and momentum from 2025 has continued into 2026 with strong demand from both surgeons and patients,” said Peter Caldini, Chief Executive Officer. “Preservé has been exceptionally well received in markets around the globe, creating market expansion in both dollar and procedure volumes. We have pioneered a new category of tissue‑preserving and minimally invasive options which offer patients the benefits of minimal anesthesia and faster recovery. This is broadly resonating with a whole new group of consumers and driving meaningful growth for plastic surgery and Establishment Labs. “We delivered these results while maintaining strong financial discipline and achieving positive adjusted EBITDA over the second half of the year. We are taking share while growing markets and expect topline growth to exceed 25% in both 2026 and 2027. Our operating model is now displaying the significant leverage we have previously shared. We are positioned for our first quarter of positive cash flow in 2026, and full year of positive cash flow in 2027.” Fourth Quarter 2025 Financial Results Total revenue for the quarter ended December 31, 2025 was $64.6 million compared to $44.5 million for the same period in 2024. Gross profit for the fourth quarter was $45.5 million, or 70.5% of revenue, compared to $30.5 million, or 68.5% of revenue, for the same period in 2024. Total operating expenses for the fourth quarter were $49.5 million, an increase of $0.3 million compared to $49.2 million in the fourth quarter of 2024. SG&A expenses remained stable at $44.0 million in the fourth quarter of 2025 and 2024. R&D expenses increased approximately $0.3 million to $5.4 million in the fourth quarter compared to $5.1 million for the same quarter a year ago. The increase was due to personnel cost and the timing of regulatory and compliance costs. Net loss from operations for the fourth quarter was $3.9 million compared to a net loss of $18.7 million in the year-ago period. Adjusted EBITDA for the fourth quarter was a positive $5.5 million compared to a loss of $13.1 million in the year-ago period. The Company’s cash balance on December 31, 2025 was $75.6 million. Cash decreased $14.8 million from December 31, 2024 and increased $4.9 million from the prior quarter, primarily as a result of operating activities and investments offset by expense reduction initiatives and additional borrowings. Conference Call and Webcast Information Establishment Labs will host a conference call and webcast today at 8:30 a.m. Eastern Time to discuss its financial results. The conference call can be accessed by dialing (877) 407-8037 (U.S. and Canada) or (201) 689-8037 (international) and using conference ID number 13758679. In addition, the live and archived webcast will be available on the Investor Relations section of the Company's website at www.establishmentlabs.com. About Establishment Labs Establishment Labs Holdings Inc. is a global medical device company dedicated to improving women’s health and wellness in breast aesthetics and reconstruction through the power of science, engineering, and technology. The Company offers a portfolio of solutions for breast health, breast aesthetics, and breast reconstruction in over 100 countries. With over four million Motiva® devices delivered to plastic and reconstructive surgeons since 2010, the Company’s products have created a new standard for safety and patient satisfaction. The company’s minimally invasive platform consists of Mia Femtech®, a unique minimally invasive experience for breast harmonization, and Preservé™, a breast tissue preserving and minimally invasive technology for breast augmentation, revision augmentation and mastopexy augmentation. GEM® is a next generation minimally invasive system for gluteal ergonomic modeling currently undergoing an IRB approved pivotal study. The Motiva Flora® tissue expander is used to improve outcomes in breast reconstruction following breast cancer and is the only regulatory-approved expander in the world with an integrated port using radio-frequency technology that is MRI conditional. Zensor™ is an RFID technology platform used to safely identify implantable devices from outside the body, and includes the company’s first biosensor Zenº™, currently part of an IRB approved pivotal study to measure core breast temperature. These solutions are supported by over 200 patents applications in 20 separate patent families worldwide and over 100 scientific and clinical studies and publications in peer reviewed journals. Establishment Labs manufactures at two facilities in Costa Rica compliant with all applicable regulatory standards under ISO13485:2024 and FDA 21 CFR 820. Please visit our website for additional information at www.establishmentlabs.com. Non-GAAP Financial Measures To supplement our financial results presented in accordance with GAAP, this release includes the following measures defined by the Securities and Exchange Commission as non-GAAP financial measures: EBITDA and Adjusted EBITDA. These non-GAAP measures are not based on any comprehensive set of accounting rules or principles and should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP, and may be different from non-GAAP measures used by other companies, limiting the usefulness of the measures for comparison with other companies. EBITDA is defined as net income or loss excluding: (1) interest expense; (2) provision for income taxes; and (3) depreciation and amortization. We consider EBITDA useful to an investor in evaluating and facilitating comparisons of our operating performance between periods by removing the impact of our capital structure (primarily interest expense) and asset base (primarily depreciation and amortization) from our operating results. We also present Adjusted EBITDA which includes additional adjustments for items such as other non-cash charges, gains or losses on extinguishment of debt, share-based compensation, contract termination costs, changes in contingent considerations payable for business acquisitions, and foreign currency gains and losses. We believe that Adjusted EBITDA provides useful supplemental information to investors regarding our ongoing operating performance that, when considered with net income and EBITDA, is beneficial to an investor's understanding of our performance. We believe disclosure of this information is also useful to investors as it provides insight into the earnings that management uses to make strategic decisions. These non-GAAP financial measures should be considered along with, but not as alternatives to, net income or loss as prescribed by GAAP as a measure of our operating performance. EBITDA and Adjusted EBITDA do not represent cash generated from operating activities under GAAP and should not be considered as alternatives to cash flows from operations or any other operating performance measure prescribed by GAAP. These measures are not measures of our liquidity, nor are indicative of funds available to fund our cash needs. These measurements do not reflect cash expenditures for long-term assets and other items that have been and will be incurred. EBITDA and Adjusted EBITDA may include funds that may not be available for management’s discretionary use due to functional requirements to conserve funds for capital expenditures, property acquisitions, and other commitments and uncertainties. Please see “Reconciliation of EBITDA and Adjusted EBITDA” for a reconciliation of these measures to net income (loss), the most directly comparable financial measure. This release also includes information about our expectations regarding Adjusted EBITDA on a forward-looking basis. We have not provided a reconciliation of such forward-looking Adjusted EBITDA information because a reconciliation of such measure to our expected GAAP net income (loss) on a forward-looking basis is not available without unreasonable efforts. The timing or amount of various reconciling items that would impact the forward-looking expectations for this non-GAAP financial measure are uncertain, depend on various factors and cannot be reasonable predicted. Such unavailable information could be material to our results computed in accordance with U.S. GAAP. Forward-Looking StatementsRead the full story here

Establishment Labs Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Guidance

Inne wiadomości firmowe